Pi-Cardia
Pi-Cardia is a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification. Pi-Cardia’s Leaflex™ catheter performs mechanical scoring of valve calcification, restoring leaflets’ mobility and improving valve hemodynamics. The Leaflex™ catheter is designed to be a cost-effective, durable standalone treatment. It can be used for patients who are not planning to undergo a transcatheter aortic valve replacement (TAVR) and it can be a means to defer TAVR in patients who may be too young for the procedure. It can also be a preparatory step for improving the outcome of TAVR in heavily-calcified and bicuspid aortic valves.
Sector
Medical Devices
Strategies
Capital
Status
Live
Website
www.pi-cardia.net
Related News
Pi-Cardia Reports First Commercial Cases with ShortCut™
Pi-Cardia receives FDA market clearance for ShortCut™
Pi-Cardia receives FDA Breakthrough Device Designation for ShortCut™
Pi-Cardia hires Gary Gratson to lead global commercialization
Pi-Cardia successfully completes enrollment in pivotal study for ShortCut™
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.